Design Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Design Therapeutics, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 9, 2026, to elect a Class II director and ratify the appointment of Ernst & Young LLP as its independent auditor.
NASDAQ
Design Therapeutics has released its proxy statement for the 2025 Annual Meeting of Stockholders, detailing proposals for director elections and auditor ratification.
NASDAQ
Design Therapeutics will hold its annual stockholders meeting on June 10, 2025, to elect directors and ratify the selection of Ernst & Young LLP as its independent accounting firm.
NASDAQ
Design Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 10, 2025, to elect directors and ratify the selection of its independent accounting firm.
NASDAQ
Design Therapeutics, Inc. will hold its annual stockholders meeting on June 13, 2024, to elect a Class III director and ratify the selection of Ernst & Young LLP as its independent auditor.
NASDAQ
Design Therapeutics announces its 2024 Annual Meeting of Stockholders to be held on June 13, 2024, to elect a director and ratify the selection of Ernst & Young LLP as the independent accounting firm.